$Innate Pharma (IPHA.US)$ NEWS Innate Pharma Presents at AAC...
NEWS
Innate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate
Innate Pharma SA announces promising preclinical data for IPH45, a novel exatecan-Antibody Drug Conjugate targeting Nectin-4, showing stronger activity than EV in urothelial tumors. IPH45 demonstrates anti-tumor efficacy in various solid tumors and EV-refractory models, with plans for IND in 2024.
🔸Promising preclinical data for IPH45 presented at AACR Annual Meeting 2024
🔸IPH45 inhibits Nectin-4 expressing tumor growth effectively in vitro and in vivo
🔸Shows stronger activity than EV in multiple urothelial carcinoma PDX models
🔸Additive anti-tumor effect to anti-PD1 treatment demonstrated in vivo
🔸Favorable safety profile in relevant animal toxicology models
🔸Potential for new solutions in various Nectin-4 expressing cancers
🔸IPH45 inhibits Nectin-4 expressing tumor growth effectively in vitro and in vivo
🔸Shows stronger activity than EV in multiple urothelial carcinoma PDX models
🔸Additive anti-tumor effect to anti-PD1 treatment demonstrated in vivo
🔸Favorable safety profile in relevant animal toxicology models
🔸Potential for new solutions in various Nectin-4 expressing cancers
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
444Followers
64Following
2814Visitors
Follow